Transform your recovery with integrative OUD care and chiropractic rehabilitation focused on achieving lasting health improvements.

Educational Abstract: Integrative, Evidence-Based Care for Opioid Use Disorder Across Special Populations

In this educational post, I present a comprehensive, first-person walkthrough of practical, evidence-based strategies for diagnosing and treating opioid use disorder (OUD) in complex clinical contexts—co-occurring mental health conditions, pregnancy, adolescents, older adults, and patients concurrently using central nervous system (CNS) depressants. I explain how I incorporate validated screening tools (PHQ-9, GAD-7, PCL-5; S2BI, BSTAD, CRAFFT), trauma-informed care, and medication-assisted treatment (MAT/MOUD: buprenorphine, methadone, naltrexone) while aligning with the latest guidance from leading researchers and agencies. I detail medication selection and safety considerations (e.g., QTc with methadone; serotonin syndrome vigilance with SSRIs/SNRIs) and illustrate practical decision-making through case-based reasoning.

This post also describes our multidisciplinary model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I, Dr. Alexander (Alex) Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, provide integrative chiropractic and functional medicine care in collaboration with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). With over 40 years of internal medicine experience, Dr. Cardenas offers medical oversight that complements my integrative chiropractic care, rehabilitation, and personal injury services—creating a seamless, patient-centered framework that emphasizes safety, outcomes, and whole-person health.

What follows is an in-depth, plain-language journey through mechanisms, methods, and actionable protocols, showing how integrative chiropractic care fits into modern OUD treatment—especially in pain, posture, stress, and functional recovery—while medical management ensures diagnostic rigor and pharmacologic safety. I will unpack the “why” behind each technique, explain the physiological underpinnings, and share clinical observations from my practice in El Paso.

Integrative Care Overview: How Our Multidisciplinary Team Treats Opioid Use Disorder

• Lead clinician, integrative chiropractic and functional medicine: Dr. Alexander (Alex) Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST
• Medical Director and Collaborative Physician: Dr. Maria Guadalupe Cardenas, MD (Internal Medicine; NPI #1164426749; Texas MD License #J2933)
• Practice: Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), El Paso, Texas
• Care domains:

• • Evidence-based OUD pharmacotherapy under medical direction (buprenorphine, methadone oversight via referral programs, naltrexone as appropriate)
  • Integrative chiropractic care for musculoskeletal pain, neuropathic irritation, and functional biomechanics
  • Functional medicine evaluation for metabolic, inflammatory, and neuroendocrine contributors
  • Rehabilitation for motor control, posture, and graded exposure to movement
  • Behavioral health referrals and peer recovery linkage
  • Personal injury medicine and coordination with legal and occupational stakeholders when applicable

How this works in practice:

• Cardenas oversees medical diagnostics, MOUD safety (e.g., QTc monitoring), and complex internal medicine comorbidities.
• I integrate spine and joint evaluation, corrective biomechanics, movement-based rehab, and neuromuscular modulation to reduce pain drivers that can fuel opioid craving and relapse.
• Together, we synchronize behavioral, pharmacologic, and biomechanical plans so each therapy reinforces the others.

Visit for background and clinical perspectives:

• Personal Injury Doctor Group (clinical observations): https://personalinjurydoctorgroup.com/
• Professional profile and publications: https://www.linkedin.com/in/dralexjimenez/

Co-Occurring Mental Health Conditions With Opioid Use Disorder: A Whole-Person Plan

Key Prevalence Insights and Why They Matter

• Approximately 21.5 million adults in the United States have co-occurring mental health and substance use disorders (Substance Abuse and Mental Health Services Administration [SAMHSA], 2023).
• Among OUD patients, rates of comorbid major depressive disorder (MDD), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) are high. Depression can affect up to half of patients with substance use disorders; anxiety around one-third; PTSD close to one-fifth (Dutta et al., 2022; GBD 2021 Mental Disorders Collaborators, 2023).

Why this drives care design:

• Untreated depression/anxiety/PTSD can diminish retention in OUD care and increase overdose/suicide risk (Olfson et al., 2020).
• Treating underlying mental health conditions improves MOUD adherence and functional outcomes (Nunes & Levin, 2004; Dugosh et al., 2016).

Screening Tools I Use and How We Implement Them

• Depression: PHQ-9 for baseline and progress tracking.
• Anxiety: GAD-7 for severity and response to care.
• PTSD: PCL-5 aligned with DSM-5 diagnostic criteria; thresholds (e.g., 31–33) guide referral for trauma-focused therapy; a 10-point reduction indicates meaningful response (Blevins et al., 2015).

How we integrate in clinic:

• At intake and at defined intervals (e.g., 4–6 weeks), our team administers these measures and documents change.
• Cardenas reviews medical comorbidities and contraindications; I coordinate nonpharmacologic interventions targeting autonomic regulation, stress biology, and somatic triggers.

Trauma-Informed Care Principles and Practical Steps

• Core principles: safety, trustworthiness and transparency, peer support, collaboration and mutuality, empowerment with choice, and sensitivity to cultural/historical/gender issues (Substance Abuse and Mental Health Services Administration, 2014).
• In practice, we:

• • Establish predictable visit structures and shared agendas.
  • Invite patient preferences for touch-based procedures (chiropractic adjustments, manual therapy).
  • Provide opt-in consent at each step; pace manual care to tolerance.
  • Offer peer recovery linkages and group resources for social buffering.

Physiological rationale:

• Chronic stress and trauma bias the autonomic nervous system toward sympathetic dominance (hypervigilance) and HPA-axis dysregulation, fueling pain amplification, sleep disruption, and craving circuitry (McEwen, 2007; Zastrow et al., 2023).
• Somatic techniques that reduce nociceptive input and modulate autonomic tone can attenuate catastrophizing and facilitate engagement in psychotherapy and MOUD (Kosek et al., 2016).

Evidence-Based Psychotherapies

• For MDD/GAD: Cognitive behavioral therapy (CBT) as first-line; for PTSD: Prolonged Exposure, Cognitive Processing Therapy, Eye Movement Desensitization and Reprocessing (EMDR) (American Psychological Association, 2017; VA/DoD, 2023).
• Our approach:

• • We identify therapists using these modalities and refer early.
  • We coordinate care notes to align exercise prescriptions with therapy goals (e.g., exposure hierarchy and graded activity).

Pharmacotherapy for Co-Occurring Conditions: How We Choose and Monitor

• First-line: SSRIs and SNRIs for MDD/GAD/PTSD (Gelenberg et al., 2010; VA/DoD, 2023). Consider:

• • Paroxetine: broad indications; higher sexual dysfunction risk.
  • Sertraline: MDD/PTSD; transient GI effects common.
  • Fluoxetine: long half-life helps with adherence; overdose risk is a counseling point in suicidal ideation.
  • Escitalopram: MDD/GAD; generally well tolerated; monitor weight.
  • Duloxetine: MDD/GAD; often fewer sexual side effects; helpful for neuropathic pain.
  • Venlafaxine: MDD/GAD; monitor blood pressure and QTc tendencies.

Safety with MOUD:

• Buprenorphine has serotonergic properties; serotonin syndrome risk is low but present when combined with SSRIs/SNRIs—the benefit often outweighs the risk given improved retention (Minozzi et al., 2020).
• Methadone: monitor QTc; citalopram and venlafaxine can add QTc burden; obtain baseline ECG, repeat after 5 half-lives of the added agent, and annually or with symptom triggers (Krantz et al., 2009).
• Naltrexone: warnings about depression and suicidality; balance risks/benefits and monitor closely (Jonas et al., 2014).

Clinical safety checklist with Dr. Cardenas:

• Baseline ECG for methadone or when adding QTc-prolonging agents.
• Electrolytes and hepatic/renal panels for dose decisions.
• Safety planning, 988 hotline counseling, and naloxone co-prescribing.

Recognizing and Managing Serotonin Syndrome

• SHIVERS: shivering; hyperreflexia/myoclonus; increased temperature; vital sign abnormalities (tachycardia, hypertension); encephalopathy; restlessness; sweating (Boyer & Shannon, 2005).
• Action plan:

• • Patient and family education at initiation of serotonergic combinations.
  • Triage severity; mild cases may resolve with medication adjustments; severe cases require urgent care.

Case Vignette: 32-Year-Old with OUD, MDD, GAD, and Chronic Low Back Pain

• Assessment highlights:

• • PHQ-9: 18 (moderately severe depression); GAD-7: 15 (severe anxiety); PCL-5: 10 (below PTSD threshold).
  • UDS positive for buprenorphine only.

• Plan:

• • Continue buprenorphine-naloxone 8 mg TID.
  • Initiate SSRI/SNRI with attention to side effects and drug interactions; offer CBT.
  • Provide naloxone; counsel on 988 and emergency plans.
  • Integrative chiropractic and rehab for degenerative disc disease—postural correction, core stabilization, graded movement, and myofascial techniques to reduce nociceptive drive.

Why chiropractic and rehab here:

• Chronic lumbar pain contributes to negative affect and sleep disruption, amplifying craving risk (Vowles et al., 2015).
• Improving segmental mechanics and core endurance reduces pain catastrophizing, increases self-efficacy, and supports retention in MOUD.

Opioid Use Disorder in Pregnancy: Compassionate, Coordinated Care That Protects Mother and Fetus

Epidemiology That Informs Urgency

• OUD in pregnancy increased several-fold from the late 1990s to the mid-2010s; neonatal withdrawal has risen in parallel, with a baby affected approximately every 24 minutes in 2021 (Hirai et al., 2021; Patrick et al., 2015).
• Rural burden can be higher due to access gaps (Haight et al., 2018).

Stigma and Its Clinical Impact

• Pregnant patients with OUD often experience stigmatizing interactions in healthcare, deterring prenatal care and increasing relapse risk (Henderson et al., 2021). We counter this by:

• • Universal screening, nonjudgmental language, and trauma-informed touch and counseling.
  • Clear, respectful consent processes and collaborative decision-making.

Universal Screening During Pregnancy

• Options we implement:

• • 4Ps Plus: Parents, Partner, Past, Present—positive screens trigger further assessment.
  • NIDA Quick Screen: past-year use patterns, including alcohol and drugs.
  • CRAFFT for patients under 27, adapted for perinatal contexts.

• Benefits:

• • Consistent pathways reduce bias and improve early risk identification.

Pregnancy Complications Associated with Opioid Use and the Physiology Behind Them

• Risks: placental abruption, fetal growth restriction, preterm birth, stillbirth, overdose (ACOG, 2017).
• Mechanisms:

• • Repeated cycles of intoxication and withdrawal create catecholamine surges and vasoconstriction, impairing uteroplacental perfusion.
  • Inconsistent nutrition and prenatal care compound fetal stress.

Neonatal Opioid Withdrawal Syndrome (NOWS)

• Diagnostic point:

• • Babies experience withdrawal, not addiction. DSM-5 substance use criteria are behavior-based and not applicable to neonates.

• Assessment:

• • Eat, Sleep, Console (ESC) focuses on functional stability (?1 oz per feed, ?1 hour sleep, consolable within 10 minutes).
  • Finnegan scoring (more detailed) remains a reference standard in some centers.

• Course and outcomes:

• • Symptoms can last days to weeks depending on maternal exposure.
  • No known lasting physical or intellectual deficits solely due to NOWS when appropriately managed (Wachman et al., 2018).

• Nonpharmacologic care:

• • Rooming-in, swaddling, skin-to-skin, and breastfeeding when appropriate; these measures reduce pharmacologic treatment needs and length of stay.

Pharmacologic Neonatal Management

• First-line therapy: morphine when nonpharmacologic measures are insufficient; clonidine or phenobarbital as adjuncts per institutional protocols.
• Naloxone is not used for neonatal withdrawal.

Breastfeeding Guidance in OUD

• Benefits:

• • Reduced infections, atopic conditions, SIDS risk; maternal benefits include reduced breast/ovarian cancer, lower postpartum depression, metabolic advantages (Victora et al., 2016).

• Contraindications:

• • Return to nonprescribed opioid use, HIV infection (context-dependent per country guidelines), or contraindicated medicines.

• Safety with MOUD:

• • Breastfeeding is compatible with maternal buprenorphine or methadone (ACOG, 2017; Reece-Stremtan et al., 2017).

Recommended Medications During Pregnancy

• First-line MOUD: buprenorphine or methadone improve maternal and neonatal outcomes and are endorsed by ACOG, SAMHSA, and WHO (ACOG, 2017; WHO, 2014).
• Naltrexone: not first-line, but not absolutely contraindicated; shared decision-making is crucial.
• Medically assisted withdrawal (detox) is not recommended due to high relapse and overdose risks (ACOG, 2017).

Integrative Care Model for Pregnancy in Our Clinic

• Dr. Cardenas leads medical oversight, MOUD initiation/continuation, and prenatal coordination.
• I support musculoskeletal comfort and function during pregnancy:

• • Gentle, pregnancy-safe spinal and pelvic adjustments to reduce low-back/pelvic girdle pain and improve gait mechanics.
  • Breathing and pelvic floor coordination, improving autonomic balance and maternal sleep.
  • Education on ergonomics and graded movement to reduce pain flares, decreasing the temptation to self-medicate.

• Behavioral health partners provide perinatal CBT or trauma-focused therapy as indicated.

Case Vignette: 28-Year-Old, G2P1, 18 Weeks, Daily Oxycodone ER 60 mg

• Plan:

• • UDS confirms opioid exposure; labs (CBC, CMP, HIV, hepatitis, STI) are within reference ranges.
  • Start buprenorphine 24 hours after last oxycodone; titrate from 2 mg to clinical stabilization (up to 24 mg/day as needed).
  • Prescribe naloxone and initiate prenatal care and psychosocial support.
  • Encourage breastfeeding postpartum if no contraindications.

• Why buprenorphine:

• • Partial agonism reduces overdose risk; better autonomy with office-based treatment; favorable neonatal outcomes (Jones et al., 2010).

• Chiropractic emphasis:

• • Reduce LBP/pelvic pain to enhance sleep and mobility; lower stress load; support adherence to prenatal appointments and MOUD.

Opioid Use Disorder in Adolescents: Prevention, Early Intervention, and Family-Centered MOUD

Epidemiologic Signals

• From 2019 to 2020, overdose deaths among ages 14–18 nearly doubled; from 2020 to 2021, they increased by an additional 20%, driven by illicitly manufactured fentanyl (CDC, 2022; Friedman et al., 2022).
• Use may be stable or down, but potency and contamination drive mortality—underscoring the importance of harm reduction and early MOUD.

Risk and Protective Factors

• Protective factors: family engagement, guardian disapproval of substance use, school connectedness, self-efficacy.
• Risk factors: adverse social determinants, early onset use, impulsivity, psychiatric disorders, maltreatment, family SUD (Yap et al., 2017).

Adolescent screening and confidentiality

• Tools:

• • S2BI: frequency-based screening for past-year use.
  • BSTAD: substance-specific days of use, broad coverage.
  • CRAFFT 2.1: behaviorally anchored risk screen; 2 positives merit further assessment.

• Confidentiality:

• • We clearly state state-specific limits (e.g., mandatory reporting thresholds).
  • One-on-one time is essential for rapport, education, and harm-reduction coaching.

Treatment Recommendations, Approvals, and Emerging Guidance

• Naloxone:

• • Educate adolescents and families on carrying and using naloxone; practice with trainers; coordinate with schools when appropriate.

• Behavioral health:

• • CBT, family-based interventions (e.g., multidimensional family therapy), and school-linked services to increase access (Dakof et al., 2015).

• MOUD approvals:

• • Buprenorphine is approved for patients 16 years and older with moderate-to-severe OUD (ASAM, 2020).
  • Naltrexone and methadone approvals begin at 18; specialized programs may have pathways with strict protocols.
  • ASAM adolescent/youth guidance updates are anticipated in 2026; we monitor closely.

Case Vignette: 16-Year-Old, Post-Surgical Opioid Exposure, Transitioned to Heroin

• Presentation: daily heroin use for six months; UDS positive for heroin, negative for fentanyl (discuss test limits and potential false negatives).
• Plan:

• • Start buprenorphine 12–24 hours after last heroin use; titrate 2–24 mg as needed.
  • Prescribe naloxone; implement psychosocial supports and school reintegration planning.
  • Family engagement with boundaries, monitoring, and reinforcement strategies.

Integrative elements:

• Rehab to address the original ankle injury—restore proprioception, graded return to sport or activity, and pain self-management skills.
• Chiropractic and manual therapy to normalize joint mechanics, reducing pain triggers and decreasing relapse risk linked to pain and stress.
• Functional medicine screening for sleep deficits, nutritional gaps, and autonomic dysregulation that can fuel anxiety and craving.

Opioid Use Disorder in Older Adults: Pharmacologic Precision and Functional Preservation

Trends and Disparities

• Since 2013, OUD diagnoses among adults 65–69 have tripled; higher rates are seen among dual-eligible Medicare/Medicaid beneficiaries, with disproportionate impact on Black Americans, Native Americans, and Alaska Natives (Huhn & Dunn, 2017; Krawczyk et al., 2022).

MOUD in Older Adults: Risks, Benefits, and Dosing Adjustments

• General approach:

• • Given the high lethality of illicit fentanyl, the benefits of MOUD usually outweigh risks.

• Methadone:

• • Monitor QTc; consider dose reduction if QTc >450 ms (men) or >460 ms (women) and correct electrolytes.
  • If creatinine clearance <10 mL/min, consider reducing dose by 50–75%; monitor for respiratory depression, especially during induction.

• Buprenorphine:

• • Safer respiratory profile due to partial agonism and ceiling effect; no renal dose adjustment; reduce dose in severe hepatic impairment and avoid certain subcutaneous formulations in moderate/severe hepatic dysfunction.

• Monitoring:

• • More frequent follow-ups to detect sedation, falls, cognitive changes, and drug-drug interactions.
  • Cardenas supervises medication changes, ECGs, and organ function labs.

Integrative supports for older adults:

• Chiropractic care to improve spinal alignment and balance mechanics, reducing fall risk and pain burden.
• Gentle mobility and strength programming to preserve independence.
• Sleep and circadian optimization to stabilize mood and reduce pain amplification.

Concurrent Benzodiazepines, CNS Depressants, and MOUD: Safety Without Withholding Life-Saving Treatment

The FDA Stance and Clinical Reasoning

• FDA urges caution about withholding MOUD in patients using benzodiazepines or other CNS depressants—treat OUD because the benefit outweighs the risk (FDA, 2017).
• We do not apply arbitrary dose caps on buprenorphine due to concurrent benzodiazepines; instead, we:

• • Intensify patient education on the risk of respiratory depression.
  • Coordinate gradual benzodiazepine tapers when clinically appropriate, replacing with evidence-based treatments (e.g., SSRI/SNRI, CBT).

CNS Depressant Categories to Assess

• Benzodiazepines (e.g., alprazolam, clonazepam)
• Non-benzodiazepine hypnotics and sedatives
• Muscle relaxants (e.g., baclofen)
• Antipsychotics (e.g., quetiapine, aripiprazole, paliperidone)
• Alcohol and gabapentinoids (consider additive sedation)

Safety Strategies with Our Team

• Dr. Cardenas coordinates slow tapers when indicated; screens for pharmacokinetic interactions.
• I implement autonomic downregulation modalities:

• • Breathing retraining, isometric holds, low-load motor control to reduce sympathetic drive and anxiety.
  • Pain education and graded exposure to reduce fear-avoidance.

• Close follow-up cadence and rescue planning with naloxone distribution.

Physiological Underpinnings: Why Combining MOUD, Integrative Chiropractic, and Rehab Works

Pain, Stress, and The Brain’s Reward Circuitry

• Chronic nociception increases central sensitization and amplifies negative affect, strengthening the value of opioids for relief (Navratilova & Porreca, 2014).
• HPA axis dysregulation and sympathetic overdrive aggravate sleep and mood, feeding a loop that increases cue reactivity and relapse risk (Koob & Volkow, 2016).
• Reducing nociceptive input and increasing self-efficacy via movement and manual care lowers craving intensity and reinforces non-drug coping pathways.

Mechanisms of Integrative Chiropractic Care in OUD-Related Pain

• Segmental biomechanics:

• • Malalignment and hypomobility create localized inflammatory microenvironments and paraspinal muscle hypertonicity; adjustments restore joint play and mechanoreceptive input that can inhibit nociception via spinal gating (Pickar, 2002).

• Proprioceptive recalibration:

• • Manual therapy and corrective exercise rebalance afferent signaling, affecting sensorimotor integration and cortical representation of painful regions (Haavik & Murphy, 2012).

• Autonomic modulation:

• • Slow, deep diaphragmatic breathing and gentle mobilizations shift vagal tone upward, reducing sympathetic arousal (Laborde et al., 2017).

• The functional medicine layer:

• • Assess and address inflammation, micronutrients, glycemic variability, and sleep—domains that modulate pain and mood.

Why Rehab Sequencing Matters

• Start with pain de-escalation and motor control before loading.
• Add graded exposure and progressive resistance to cultivate resilience.
• Incorporate goal-driven tasks to rebuild value-consistent activities (e.g., playing with children, returning to work).

Clinical Observations from Our Practice in El Paso

• Common patterns:

• • Post-injury kinetic chain dysfunction leads to compensatory pain in adjacent regions.
  • Correcting hip hinge mechanics and core control often reduces lumbar pain more reliably than passive modalities alone.

• Implementation:

• • Baseline movement screen; identify weak links.
  • Microdosing movement throughout the day to sustain neuroplastic change.

• Results we observe:

• • Improved adherence to MOUD and therapy when pain is reduced, and sleep improves.
  • Patients report decreased catastrophizing and enhanced confidence in activity.

For ongoing clinical blogs and case reflections:

• Personal Injury Doctor Group: https://personalinjurydoctorgroup.com/
• LinkedIn professional insights: https://www.linkedin.com/in/dralexjimenez/

Protocols and Decision Pathways: From Intake to Long-Term Recovery

Intake Framework

• Medical: full history, medication reconciliation, ECG if indicated, labs (CBC, CMP, liver/renal, infections), pregnancy test when relevant.
• Behavioral: PHQ-9, GAD-7, PCL-5; adolescent tools (S2BI, BSTAD, CRAFFT).
• Pain/Function: region-specific exams, range of motion, palpation, functional screens (sit-to-stand, gait analysis).
• Social: support mapping, barriers, SDoH needs, peer recovery access.
• Safety: naloxone distribution, 988 hotline education, crisis plan.

MOUD Selection

• Buprenorphine:

• • Default for ambulatory care, partial agonist safety, office-based induction or low-dose (microinduction) when needed.

• Methadone:

• • Indicated when high tolerance or structural barriers to buprenorphine exist; coordinate with OTP, monitor QTc.

• Naltrexone:

• • Consider only when sustained opioid abstinence is documented and patient preference aligns; monitor mood.

Psychotherapy and Psychiatric Medications

• Match modality to diagnosis and patient readiness.
• SSRIs/SNRIs:

• • Choose based on side effect tolerability, comorbid pain, and QTc considerations.

• Monitor:

• • Weekly/biweekly in the early phase; switch or augment if there is minimal response by 4–6 weeks.

Integrative Chiropractic and Rehab Progression

• Phase 1: Pain modulation—gentle adjustments, soft tissue techniques, isometrics, diaphragmatic breathing, sleep hygiene.
• Phase 2: Motor control—transverse abdominis and multifidus activation, hip abductor strength, scapular control.
• Phase 3: Load tolerance—progressive resistance, dynamic balance, mechanotransduction to support connective tissue resilience.
• Phase 4: Return to role—task-specific training and relapse prevention strategies for pain flares.

Pregnancy-Specific Adaptations

• Side-lying or modified-prone positioning; avoid sustained supine after mid-gestation.
• Low-velocity mobilizations; sacroiliac and pubic symphysis stabilization.
• Pelvic floor coordination; prenatal/postnatal education for safe activity.

Adolescent-Specific Adaptations

• Family engagement with confidentiality boundaries.
• School liaison to support attendance and accommodations.
• Sports medicine focus on safe return to activity.

Older Adult-Specific Adaptations

• Fall risk screening and balance training.
• Polypharmacy review with de-prescribing consults.
• Lower-intensity, higher-frequency sessions to consolidate gains.

Enhancing Health Together: Embracing Multidisciplinary Evaluation and Treatment- Video

Safety Monitoring and Quality Assurance

ECG and QTc

• Baseline and follow-up ECGs when methadone or QTc-prolonging agents are used; repeat after 5 half-lives of new QTc-active meds, and annually or with symptoms (palpitations, syncope).

Serotonin syndrome watch

• Education on SHIVERS; early contact mechanisms for symptom escalation.

Hepatic and renal labs

• At baseline and at defined intervals for MOUD and psychotropics.

Diversion and adherence

• Periodic observed dosing when risk is high; prescription monitoring programs; pill counts as appropriate.
• Use of long-acting buprenorphine formulations when adherence is a challenge and hepatic status allows.

Documentation and outcomes tracking

• Standardized symptom scores, functional metrics, and opioid craving assessments.
• Return-to-work status, sleep quality measures, and pain interference scores.

How Dr. Cardenas and I Coordinate Care at Injury Medical Clinic PA

• Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749; Texas MD License #J2933), Board Certified in Internal Medicine, serves as Medical Director and Collaborative Physician at our clinic.
• Workflow:

• • Joint case review: intake findings, ECG/lab results, mental health screens, and pain/function data.
  • MOUD plan under Dr. Cardenas’s medical oversight; I establish the integrative chiropractic and rehab plan.
  • Regular case conferences and shared outcome dashboards to adjust therapy.
  • External coordination: obstetricians, psychiatrists, OTPs, school counselors, and legal/occupational partners as needed.

Why this matters:

• Medical safety and pharmacovigilance are tightly coupled with nonpharmacologic pain and function restoration—reducing relapse drivers and enhancing patient agency.

Practical Pearls and Common Pitfalls

• Do not delay MOUD due to benzodiazepine use—educate, monitor, and taper when possible.
• Screen for PTSD intentionally; PCL-5 can be overlooked but is critical for therapy selection.
• Do not pursue detox in pregnancy; prioritize buprenorphine or methadone per guidelines.
• Combat stigma proactively; universal screening and trauma-informed language reduce care avoidance.
• Use duloxetine when depression coexists with neuropathic pain, considering sexual side effect profiles.
• With methadone, consistently monitor QTc, electrolytes, and interacting medications.
• For adolescents, involve families and schools; normalize naloxone carrying in high-risk settings.
• For older adults, reduce fall risk with balance and strength training integrated into clinic and home programs.

Frequently Asked Questions

• Is buprenorphine safe while breastfeeding?

• • Yes, when used as prescribed; it is recommended and associated with better neonatal outcomes.

• Should I avoid SSRIs with buprenorphine due to serotonin syndrome?

• • The risk is low; combined treatment improves retention and outcomes. Educate and monitor.

• Can chiropractic care help reduce opioid cravings?

• • Indirectly—by decreasing pain, improving sleep, and increasing autonomic balance and self-efficacy, which reduces triggers linked to craving and relapse.

• What if a patient is on methadone and citalopram?

• • Evaluate QTc, consider alternatives if QTc is prolonged, monitor symptoms, and correct electrolytes.

• Is naltrexone appropriate in pregnancy?

• • Not first-line. Consider only with comprehensive counseling and when the risk-benefit calculus strongly favors it.

Final Takeaways

• Treat co-occurring depression, anxiety, and PTSD alongside OUD; integrated care improves retention and recovery.
• In pregnancy, MOUD with buprenorphine or methadone is recommended; detoxification increases relapse and overdose risks.
• Adolescents benefit from early MOUD (buprenorphine ?16), family involvement, school supports, and naloxone.
• Older adults require careful dose adjustments and falls prevention; buprenorphine is often a safer first choice.
• Do not withhold MOUD due to benzodiazepine or CNS depressant co-use; prioritize safety education and tapering plans.
• Integrative chiropractic and rehabilitation reduce pain and autonomic distress, strengthening recovery capacity.

Our team at Injury Medical Clinic PA in El Paso unites internal medicine oversight and integrative chiropractic/functional medicine—bridging modern pharmacotherapy with biomechanics, movement, and psychosocial supports. With Dr. Maria Guadalupe Cardenas’s medical leadership and our coordinated, trauma-informed methods, we aim to deliver comprehensive, compassionate, evidence-aligned care for every stage of the OUD journey.

For clinical insights and ongoing updates:

• Personal Injury Doctor Group: https://personalinjurydoctorgroup.com/
• LinkedIn: https://www.linkedin.com/in/dralexjimenez/

References

• American College of Obstetricians and Gynecologists. (2017). Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy
• American Psychological Association. (2017). Clinical practice guideline for the treatment of PTSD. https://www.apa.org/ptsd-guideline
• ASAM. (2020). National practice guideline for the treatment of opioid use disorder: 2020 focused update. https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline
• Blevins, C. A., Weathers, F. W., et al. (2015). The Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5). Journal of Traumatic Stress, 28(6), 489–498. https://doi.org/10.1002/jts.22059
• Boyer, E. W., & Shannon, M. (2005). The serotonin syndrome. NEJM, 352, 1112–1120. https://www.nejm.org/doi/full/10.1056/NEJMra041867
• Centers for Disease Control and Prevention. (2022). Provisional drug overdose death counts. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
• Dakof, G. A., et al. (2015). Multidimensional family therapy for adolescent substance use. Journal of Substance Abuse Treatment, 58, 40–49. https://doi.org/10.1016/j.jsat.2015.06.017
• Dugosh, K., et al. (2016). A systematic review on psychosocial interventions in conjunction with medications for opioid use disorder. Journal of Addiction Medicine, 10(2), 93–103. https://doi.org/10.1097/ADM.0000000000000193
• Dutta, R., et al. (2022). Comorbidity of mental disorders and substance use disorders. The Lancet Psychiatry, 9(10), 825–839. https://doi.org/10.1016/S2215-0366(22)00184-9
• Food and Drug Administration. (2017). FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants. https://www.fda.gov/
• Friedman, J., et al. (2022). Trends in overdose deaths among US adolescents. JAMA, 327(14), 1398–1400. https://doi.org/10.1001/jama.2022.4701
• Gelenberg, A. J., et al. (2010). Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association. https://psychiatryonline.org/
• GBD 2021 Mental Disorders Collaborators. (2023). Global burden of mental disorders. The Lancet Psychiatry, 10(1), 17–44. https://doi.org/10.1016/S2215-0366(22)00395-6
• Haavik, H., & Murphy, B. (2012). The role of spinal manipulation in motor control. Journal of Electromyography and Kinesiology, 22(5), 768–776. https://doi.org/10.1016/j.jelekin.2012.02.012
• Haight, S. C., et al. (2018). OUD among women of reproductive age. MMWR, 67(31), 845–849. https://www.cdc.gov/mmwr/volumes/67/wr/mm6731a1.htm
• Henderson, J., et al. (2021). Stigma in perinatal substance use. Women and Birth, 34(3), e277–e286. https://doi.org/10.1016/j.wombi.2020.01.009
• Hirai, A. H., et al. (2021). Neonatal abstinence syndrome and maternal opioid use. Pediatrics, 147(5), e2020029076. https://doi.org/10.1542/peds.2020-029076
• Huhn, A. S., & Dunn, K. E. (2017). Why aren’t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment, 78, 1–7. https://doi.org/10.1016/j.jsat.2017.04.005
• Jones, H. E., et al. (2010). Neonatal abstinence syndrome after methadone or buprenorphine exposure. NEJM, 363(24), 2320–2331. https://doi.org/10.1056/NEJMoa1005359
• Jonas, D. E., et al. (2014). Pharmacotherapy for adults with alcohol use disorder. JAMA, 311(18), 1889–1900. https://doi.org/10.1001/jama.2014.3628
• Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction. The Lancet Psychiatry, 3(8), 760–773. https://doi.org/10.1016/S2215-0366(16)00104-8
• Kosek, E., et al. (2016). Evidence for central sensitization in chronic pain. Pain, 157(11), 2341–2344. https://doi.org/10.1097/j.pain.0000000000000705
• Krantz, M. J., et al. (2009). Torsade de pointes and methadone. Pharmacotherapy, 29(6), 642–655. https://doi.org/10.1592/phco.29.6.642
• Krawczyk, N., et al. (2022). Racial/ethnic disparities in MOUD. Drug and Alcohol Dependence, 232, 109266. https://doi.org/10.1016/j.drugalcdep.2022.109266
• Laborde, S., et al. (2017). Vagal tone and self-regulation. Frontiers in Neuroscience, 11, 278. https://doi.org/10.3389/fnins.2017.00278
• McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation. Physiological Reviews, 87(3), 873–904. https://doi.org/10.1152/physrev.00041.2006
• Minozzi, S., et al. (2020). Maintenance treatments for OUD. Cochrane Database of Systematic Reviews, CD002207. https://doi.org/10.1002/14651858.CD002207.pub5
• Navratilova, E., & Porreca, F. (2014). Reward and relief: opioid reward circuits in pain relief. Trends in Neurosciences, 37(10), 539–546. https://doi.org/10.1016/j.tins.2014.07.009
• Nunes, E. V., & Levin, F. R. (2004). Treatment of depression in patients with substance use disorders. Biological Psychiatry, 56(10), 732–739. https://doi.org/10.1016/j.biopsych.2004.06.012
• Olfson, M., et al. (2020). Suicide and OUD. American Journal of Psychiatry, 177(1), 19–27. https://doi.org/10.1176/appi.ajp.2019.19030215
• Patrick, S. W., et al. (2015). Increasing incidence of neonatal abstinence syndrome. J Perinatol, 35(8), 650–655. https://doi.org/10.1038/jp.2015.36
• Pickar, J. G. (2002). Neurophysiological effects of spinal manipulation. Spine Journal, 2(5), 357–371. https://doi.org/10.1016/S1529-9430(02)00400-X
• Reece-Stremtan, S., & Marinelli, K. A. (2017). ABM Clinical Protocol #21: Breastfeeding and substance use. Breastfeeding Medicine, 12(3), 135–141. https://doi.org/10.1089/bfm.2017.9992
• Substance Abuse and Mental Health Services Administration. (2014). SAMHSA’s Concept of Trauma and Guidance for a Trauma-Informed Approach. https://store.samhsa.gov/
• Substance Abuse and Mental Health Services Administration. (2023). Key substance use and mental health indicators in the United States: 2022 NSDUH. https://www.samhsa.gov/
• VA/DoD. (2023). Clinical practice guideline for the management of PTSD and acute stress disorder. https://www.healthquality.va.gov/
• Victora, C. G., et al. (2016). Breastfeeding and health outcomes. The Lancet, 387(10017), 475–490. https://doi.org/10.1016/S0140-6736(15)01074-3
• Vowles, K. E., et al. (2015). Pain and opioid misuse. PAIN, 156(4), 569–576. https://doi.org/10.1097/j.pain.0000000000000108
• Wachman, E. M., et al. (2018). Neonatal opioid withdrawal syndrome: Advances and controversies. Clinics in Perinatology, 45(2), 283–296. https://doi.org/10.1016/j.clp.2018.01.010
• World Health Organization. (2014). Guidelines for the identification and management of substance use and substance use disorders in pregnancy. https://www.who.int/

SEO tags: opioid use disorder, OUD treatment, buprenorphine, methadone, naltrexone, pregnancy and OUD, neonatal opioid withdrawal syndrome, NOWS, adolescent OUD, older adults OUD, benzodiazepines and MOUD, serotonin syndrome, QTc prolongation, trauma-informed care, PHQ-9, GAD-7, PCL-5, S2BI, BSTAD, CRAFFT, integrative chiropractic, functional medicine, rehabilitation, El Paso Injury Medical Clinic, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas